Rafferty Asset Management Portfolio holdings
AUM
$30.3B
1-Year Return
18.89%
This Quarter Return
+7.65%
1 Year Return
+18.89%
3 Year Return
+101.02%
5 Year Return
+164.75%
10 Year Return
+314.44%
AUM
$8.27B
AUM Growth
+$1.17B
(+17%)
Cap. Flow
+$750M
Cap. Flow
% of AUM
9.07%
Top 10 Holdings %
Top 10 Hldgs %
43.67%
Holding
1,071
New
101
Increased
574
Reduced
272
Closed
122
Top Buys
| 1 |
VanEck Gold Miners ETF
GDX
|
$287M |
| 2 |
VanEck Junior Gold Miners ETF
GDXJ
|
$258M |
| 3 |
Apple
AAPL
|
$67.9M |
| 4 |
Microsoft
MSFT
|
$62.7M |
| 5 |
iShares China Large-Cap ETF
FXI
|
$59.7M |
Top Sells
| 1 |
iShares Russell 2000 ETF
IWM
|
$189M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
$112M |
| 3 |
Visa
V
|
$56.8M |
| 4 |
Mastercard
MA
|
$50M |
| 5 |
iShares MSCI Emerging Markets ETF
EEM
|
$42.1M |
Sector Composition
| 1 | Technology | 27.51% |
| 2 | Financials | 14.83% |
| 3 | Healthcare | 4.08% |
| 4 | Consumer Discretionary | 3.56% |
| 5 | Industrials | 3.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
426
Halozyme
HALO
$8.76B
| $1.93M | 0.02% |
73,351
+31,506
| +75% | +$828K |
|
|
CLVS
427
DELISTED
Clovis Oncology, Inc.
CLVS
| $1.92M | 0.02% |
328,503
+187,227
| +133% | +$1.09M |
|
428
BioXcel Therapeutics
BTAI
$55.2M
| $1.91M | 0.02% |
2,760
+1,887
| +216% | +$1.31M |
|
429
First American
FAF
$6.83B
| $1.91M | 0.02% |
37,453
+15,125
| +68% | +$770K |
|
430
Franklin Resources
BEN
$13B
| $1.9M | 0.02% |
93,553
+37,595
| +67% | +$765K |
|
431
Neurocrine Biosciences
NBIX
$14.3B
| $1.9M | 0.02% |
19,766
+8,621
| +77% | +$829K |
|
432
UFP Industries
UFPI
$6.08B
| $1.9M | 0.02% |
33,619
+4,908
| +17% | +$277K |
|
433
Bank OZK
OZK
$5.9B
| $1.9M | 0.02% |
89,026
+20,927
| +31% | +$446K |
|
434
Alkermes
ALKS
$4.94B
| $1.89M | 0.02% |
114,032
+55,649
| +95% | +$922K |
|
435
Agios Pharmaceuticals
AGIO
$2.09B
| $1.88M | 0.02% |
53,671
+33,414
| +165% | +$1.17M |
|
436
Leidos
LDOS
$23B
| $1.88M | 0.02% |
21,050
+5,149
| +32% | +$459K |
|
437
CareDx
CDNA
$736M
| $1.87M | 0.02% |
49,378
+26,715
| +118% | +$1.01M |
|
|
EVA
438
DELISTED
Enviva Inc.
EVA
| $1.87M | 0.02% |
46,472
+2,274
| +5% | +$91.6K |
|
|
AJRD
439
DELISTED
Aerojet Rocketdyne Holdings, Inc.
AJRD
| $1.86M | 0.02% |
46,695
+6,654
| +17% | +$265K |
|
440
Ligand Pharmaceuticals
LGND
$3.25B
| $1.86M | 0.02% |
31,254
+16,037
| +105% | +$953K |
|
441
Editas Medicine
EDIT
$248M
| $1.86M | 0.02% |
66,159
+32,685
| +98% | +$917K |
|
442
Coherus Oncology, Inc. Common Stock
CHRS
$150M
| $1.85M | 0.02% |
100,956
+41,571
| +70% | +$763K |
|
|
PACW
443
DELISTED
PacWest Bancorp
PACW
| $1.83M | 0.02% |
107,256
+28,403
| +36% | +$485K |
|
444
Erie Indemnity
ERIE
$17.5B
| $1.83M | 0.02% |
8,683
+3,494
| +67% | +$735K |
|
445
Louisiana-Pacific
LPX
$6.9B
| $1.82M | 0.02% |
61,726
+8,995
| +17% | +$266K |
|
|
VBIV
446
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $1.82M | 0.02% |
+21,198
| New | +$1.82M |
|
447
Zoetis
ZTS
$67.9B
| $1.81M | 0.02% |
10,963
-1,947
| -15% | -$322K |
|
448
Ionis Pharmaceuticals
IONS
$9.76B
| $1.81M | 0.02% |
38,179
+21,695
| +132% | +$1.03M |
|
449
BioCryst Pharmaceuticals
BCRX
$1.74B
| $1.81M | 0.02% |
526,302
+303,685
| +136% | +$1.04M |
|
450
Deere & Co
DE
$128B
| $1.81M | 0.02% |
+8,144
| New | +$1.81M |
|